DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021

Rhea-AI Summary

DBV Technologies will report its full year 2020 financial results on March 4, 2021. The clinical-stage biopharmaceutical company will hold a conference call and live audio webcast at 5:00 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the call via specified teleconferencing numbers and also via a live webcast available on the company's website. The company is focused on developing Viaskin™, a proprietary technology for treating food allergies through a non-invasive method.

Positive

• Upcoming full year 2020 financial results announcement may reflect positive growth.
• Focus on innovative Viaskin™ technology for food allergies has strong market potential.

Negative

• No specific financial metrics or guidance provided in the PR raises uncertainty about performance expectations.

Montrouge, France, March 1, 2020

DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, March 4, 2021, at 5:00 p.m. ET/23:00 CET to report full year 2020 financial results and provide a corporate update.

This call is accessible via the below teleconferencing numbers, followed by the reference ID: 50114481.

• United States: (866) 866-1333                             
• Canada: (866)-215-5508
• United Kingdom: 0808 238 9578                       
• France: 0805 102 604

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies 
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

When will DBV Technologies report its financial results for 2020?

DBV Technologies will report its financial results for 2020 on March 4, 2021.

What time will the DBV Technologies conference call take place?

The conference call will take place at 5:00 p.m. ET on March 4, 2021.

How can I access the DBV Technologies financial results conference call?

The conference call can be accessed via specified teleconferencing numbers or through a live audio webcast on DBV Technologies' website.

What is the focus of DBV Technologies?

DBV Technologies is focused on developing Viaskin™, a technology aimed at treating food allergies through skin-based immunotherapy.